NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ansa Biotechnologies

Ansa Biotechnologies

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://ansabio.com/

Last Round

Series B

Oct 1, 2025

Total Funding Raised

$132.59M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ansa Biotechnologies is a biotechnology company that provides enzymatic DNA synthesis services to accelerate biological research and synthetic biology innovation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Non-AI

Keywords

DNA synthesisenzymatic DNA synthesissynthetic biologyclonal DNAgene synthesislong-sequence DNAsynthetic DNADNA constructssynbiocustom gene synthesisDNA foundrygenetic engineeringdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ansa Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

Ansa Biotechnologies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ansa Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 1, 2025
Series AApr 11, 2022
GrantApr 15, 2021
SeedSep 14, 2020
Pre SeedDec 1, 2018

Key People

Founding team and executive leadership

Jason T. Gammack

Chief Executive Officer

Executive Team

Sebastian Palluk

CTO

Executive Team

Matthias Arenskötter

Chief Operating Officer

Executive Team

Ansa Biotechnologies Investors

Notable investors and investment history

Ansa Biotechnologies investors
InvestorRounds
Horizons VenturesSeed, Series A
RA Capital ManagementSeries A
Fall Line CapitalSeries B
Codon CapitalSeries A
PEAK6 Strategic CapitalSeries A
Altitude Life Science VenturesSeries A, Series B
Carbon Silicon VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    Will present at SynBioBeta 2026 conference in San Jose, CA.

  • Mar 31, 2026

    Matthias Arenskötter appointed as the new COO.

Ansa Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ansa Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ansa Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range75
Year Founded2018
Last FundingOct 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.